Nanomedicine is an area of nanotechnology dedicated to the development of diagnostic and therapeutic solutions for medical purposes. Given the number of scientific articles published in this area of research and the number of pharmacological products on the market, oncology is the principal field of investigation in nanomedicine. In fact, the first pharmaceutical nanomedical products, Doxil©, and Myocet© were designed for oncological applications based on nano-seized liposomal technologies. The start of this tumor targeting was based on the discovery of the Enhanced Permeation and Retention Effect (EPR), which is a passive accumulation of nanocarriers into tumor tissues. The EPR effect stimulated the development of a huge number of scientific projects and the rapid development of nanomedical products for cancer therapy. After almost three decades of efforts to understand the EPR effect, researchers reached a consensus that other aspects, beyond EPR, are important for optimal nonmedical product design.
The literature has moved from this previous “nanomedicine dogma” to a more diverse technology approach that includes controlled release, cross biological barriers, reduced toxicity, activation of the immune system, induction of immunogenic cell death and more. Nowadays researchers understand nanomedicine as a very versatile technological platform to improve cancer therapy and diagnosis.
The aim of this Research Topic is to describe the most recent science and technology advances in the field of nanomedicine with cancer targets and therapeutics. We welcome submissions of Original Research, Review, Mini-Review and Clinical Trial articles focusing on but not limited to the following subtopics:
1) Targeting nanoparticles to tumors.
2) Immunological modulation and nanotechnology.
3) Nanoparticles for targeting tumor imaging.
4) Immunogenic cell death and nanotechnology.
5) Triggering Immune System with Nanoparticles.
6) The evolving science and engineering of nanoparticles.
7) The combination of nanoparticles with other cancer therapeutics.
8) Clinical trials using nanoparticles.
9) New Nanomedicine perspectives.
Nanomedicine is an area of nanotechnology dedicated to the development of diagnostic and therapeutic solutions for medical purposes. Given the number of scientific articles published in this area of research and the number of pharmacological products on the market, oncology is the principal field of investigation in nanomedicine. In fact, the first pharmaceutical nanomedical products, Doxil©, and Myocet© were designed for oncological applications based on nano-seized liposomal technologies. The start of this tumor targeting was based on the discovery of the Enhanced Permeation and Retention Effect (EPR), which is a passive accumulation of nanocarriers into tumor tissues. The EPR effect stimulated the development of a huge number of scientific projects and the rapid development of nanomedical products for cancer therapy. After almost three decades of efforts to understand the EPR effect, researchers reached a consensus that other aspects, beyond EPR, are important for optimal nonmedical product design.
The literature has moved from this previous “nanomedicine dogma” to a more diverse technology approach that includes controlled release, cross biological barriers, reduced toxicity, activation of the immune system, induction of immunogenic cell death and more. Nowadays researchers understand nanomedicine as a very versatile technological platform to improve cancer therapy and diagnosis.
The aim of this Research Topic is to describe the most recent science and technology advances in the field of nanomedicine with cancer targets and therapeutics. We welcome submissions of Original Research, Review, Mini-Review and Clinical Trial articles focusing on but not limited to the following subtopics:
1) Targeting nanoparticles to tumors.
2) Immunological modulation and nanotechnology.
3) Nanoparticles for targeting tumor imaging.
4) Immunogenic cell death and nanotechnology.
5) Triggering Immune System with Nanoparticles.
6) The evolving science and engineering of nanoparticles.
7) The combination of nanoparticles with other cancer therapeutics.
8) Clinical trials using nanoparticles.
9) New Nanomedicine perspectives.
